• 28S rRNA Expansion Segments Architect Multilayered Nucleoli

  2026-07-21

  Wei et al. elucidate how multivalent expansion segments within 28S rRNA are critical for assembling the multilayered structure of the eukaryotic nucleolus. Their findings reveal that these RNA modules serve as architectural elements, and transferring them between species can reconstitute nucleolar layering in vitro—providing new mechanistic insight into nucleolar complexity.

• Exosomal SNORD52 Drives M2 Macrophage Polarization via JAK2/

  2026-07-21

  A recent study reveals that exosomal SNORD52 from hepatoma cells promotes M2 macrophage polarization by activating the JAK2/STAT6 pathway. This mechanism highlights a novel exosome-mediated axis in hepatocellular carcinoma progression, offering new targets for immune modulation in cancer research.

• Pexmetinib (ARRY-614) in Cytokine Inhibition: Workflows & In

  2026-07-20

  Pexmetinib (ARRY-614) stands out for its dual inhibition of p38 MAPK and Tie2, enabling precise modulation of inflammatory pathways in both in vitro and translational models. This guide translates recent structural and mechanistic advances into actionable protocols and troubleshooting strategies for researchers tackling cytokine synthesis and myelodysplastic syndromes.

• Norovirus Exploits NINJ1 for Selective Protein Secretion

  2026-07-20

  Song et al. reveal a novel mechanism by which murine norovirus hijacks host NINJ1 to specifically secrete the viral protein NS1 during programmed cell death. This study identifies NINJ1 as a selective mediator in viral-host interactions, offering new insight into unconventional protein secretion pathways with implications for antiviral strategies.

• DiscoveryProbe FDA-approved Drug Library in Targeted Screeni

  2026-07-19

  The DiscoveryProbe FDA-approved Drug Library enables robust, high-throughput drug repositioning and novel target identification across cancer and neurodegenerative research. Its pre-dissolved, quality-controlled format and diversity of approved compounds let scientists efficiently translate bench findings into actionable leads.

• GPNMB-Based Model Enhances ESCC Immunotherapy Response Predi

  2026-07-18

  This study introduces a multimodal model utilizing circulating GPNMB, CAF-Epi niche features, and clinical data to predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). The model's mechanistic insight into GPNMB-mediated CD8+ T cell exhaustion offers new avenues for patient stratification and therapy optimization.

• Annexin V-Cy5 Apoptosis Kit: Precision Analysis in Lysosomal

  2026-07-17

  Explore advanced applications of the Annexin V-Cy5 Apoptosis Kit in dissecting apoptosis under lysosomal stress, with a focus on neuroimmunology and microglial biology. This article delivers new insights for researchers seeking rigorous, workflow-ready strategies for apoptosis detection.

• PDHA1 Succinylation and α-Ketoglutarate in Cholangiocarcinom

  2026-07-17

  This study reveals that succinylation of PDHA1 at lysine 83 in cholangiocarcinoma drives metabolic reprogramming, leading to alpha-ketoglutarate accumulation and suppression of macrophage antigen presentation via OXGR1-MAPK signaling. Targeting PDHA1 succinylation emerges as a potential strategy to overcome chemotherapy resistance and modulate tumor-immune interactions.

• Annexin V-Cy5 Apoptosis Kit: Illuminating Apoptosis in Rever

  2026-07-16

  Explore how the Annexin V-Cy5 Apoptosis Kit enables precise apoptosis detection in complex models of reversible lysosomal stress. This article offers novel insights for researchers seeking to dissect apoptotic and non-apoptotic mechanisms in neuroimmune and toxicology studies.

• Applied Use of the DiscoveryProbe FDA-approved Drug Library

  2026-07-16

  Harness the DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) to streamline high-throughput drug screening, accelerate drug repositioning, and enable robust pharmacological target identification. This article bridges experimental workflows and troubleshooting strategies, with actionable insights grounded in recent reference studies and scenario-driven literature.

• Annexin V-Cy5 Apoptosis Kit: Precision Apoptosis Detection i

  2026-07-15

  The Annexin V-Cy5 Apoptosis Kit streamlines apoptosis detection in live neuroimmune models, delivering high-sensitivity results in just 10 minutes. Its unique Cy5 fluorescence and one-step workflow enable researchers to dissect microglia responses to lysosomal stress with unmatched clarity and reproducibility.

• GLI Inhibition, Tumor Immune Evasion, and Translational Hori

  2026-07-15

  This thought-leadership article synthesizes mechanistic insight into GLI2-driven tumor immune evasion, evidence-based guidance for incorporating GANT61 as a selective GLI inhibitor in translational cancer research, and actionable protocol strategies. Integrating recent advances—including the role of GLI2 in immunotherapy resistance—this piece bridges biological rationale with experimental and clinical workflow, while situating GANT61’s value versus the broader competitive landscape and existing content.

• Epoxomicin: Advanced Proteasome Inhibitor for Pathway Resear

  2026-07-14

  Epoxomicin distinguishes itself as a gold-standard, irreversible proteasome inhibitor, ideal for dissecting the ubiquitin-proteasome pathway in cellular and disease models. This guide delivers hands-on workflows, troubleshooting strategies, and insights from recent viral immunity research to optimize your experimental outcomes.

• Rapakinin-Induced Vasorelaxation via PGI2–IP and CCK1 Pathwa

  2026-07-14

  The referenced study establishes rapakinin, a peptide from rapeseed protein, as a vasorelaxant that lowers blood pressure in hypertensive rats by activating the prostaglandin I2 (PGI2)–IP receptor pathway, followed by the cholecystokinin (CCK1) receptor. This work clarifies a novel, nitric oxide–independent mechanism for vascular relaxation, providing new insights for antihypertensive research and potential gut-cardiovascular therapeutic intersections.

• Lovastatin: Mechanism, Benchmarks, and Research Integration

  2026-07-13

  Lovastatin is a potent HMG-CoA reductase inhibitor that blocks cholesterol biosynthesis at nanomolar concentrations. It induces apoptosis in fibroblasts and cancer cells, with measurable effects on proliferation and macrophage efferocytosis. This article details its mechanism, evidence, and key workflow parameters for advanced research.

15740 records 1/1050 page Next 12345 下5页 Last page